# Retina is a Marker for Cerebrovascular Heath

Study · id `cardio:ct-nct04753970` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04753970](<https://clinicaltrials.gov/study/NCT04753970>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04753970

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT04753970. Randomized; no masking; primary purpose prevention. Start 2021-02-09 (actual); primary completion 2030-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 1/2
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT04753970, source copy `cardio:ctgov-nct04753970-2026-08-03`, retrieved 2026-10-26)
- Started: 2021-02-09 (actual) (ClinicalTrials.gov record NCT04753970, source copy `cardio:ctgov-nct04753970-2026-08-03`, retrieved 2026-10-26)
- Primary completion: 2030-06 (anticipated) (ClinicalTrials.gov record NCT04753970, source copy `cardio:ctgov-nct04753970-2026-08-03`, retrieved 2026-10-26)
- Completion: 2030-06 (anticipated) (ClinicalTrials.gov record NCT04753970, source copy `cardio:ctgov-nct04753970-2026-08-03`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04753970, source copy `cardio:ctgov-nct04753970-2026-08-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04753970-2026-08-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Retina is a Marker for Cerebrovascular Heath
- Condition: Cerebral Small Vessel Diseases
- Condition: Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy
- Condition: Cerebral Microbleeding
- Condition: Sporadic White Matter Disease
- Intervention (Drug): Cilostazol
- Lead sponsor: Mayo Clinic
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cerebral small vessel disease (`cardio:cerebral-small-vessel-disease`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Mayo Clinic (`cardio:org-mayo-clinic`)

## Provenance

Content hash: 3a8c755a1511caf5ff4f6caf6b3f899e11e0fb7fe1ead00c975d47812c18524b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
